uric acid has been researched along with Cushing Syndrome in 9 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Cushing Syndrome: A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pathogenesis of nephrolithiasis in Cushing's syndrome is still not completely clarified." | 1.32 | Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. ( Colao, A; Di Somma, C; Faggiano, A; Filippella, M; Lombardi, G; Melis, D; Petretta, M; Pivonello, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anagnostis, P | 1 |
| Athyros, VG | 1 |
| Tziomalos, K | 1 |
| Karagiannis, A | 1 |
| Mikhailidis, DP | 1 |
| Faggiano, A | 1 |
| Pivonello, R | 1 |
| Melis, D | 1 |
| Filippella, M | 1 |
| Di Somma, C | 1 |
| Petretta, M | 1 |
| Lombardi, G | 1 |
| Colao, A | 1 |
| DANOWSKI, TS | 1 |
| SARVER, ME | 1 |
| MOSES, C | 1 |
| BONESSI, JV | 1 |
| Keller, U | 1 |
| Staub, JJ | 1 |
| Hauenstein, M | 1 |
| Müller, J | 1 |
| Ohnishi, T | 1 |
| Suzuki, T | 1 |
| Watanabe, S | 1 |
| Takahashi, H | 1 |
| Garrapa, GG | 1 |
| Pantanetti, P | 1 |
| Arnaldi, G | 1 |
| Mantero, F | 1 |
| Faloia, E | 1 |
| Reach, G | 1 |
| Elkik, F | 1 |
| Parry, C | 1 |
| Corvol, P | 1 |
| Milleiz, P | 1 |
| Gorden, P | 1 |
| Becker, CE | 1 |
| Levey, GS | 1 |
| Roth, J | 1 |
| Cottier, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals[NCT01419535] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2011-11-29 | Completed | ||
| Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism[NCT01990560] | Phase 4 | 8 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The adipose tissue insulin resistance index (Adipo-IR), a surrogate measure for fasting adipose-tissue insulin resistance, was calculated as the product of fasting insulin and fasting free fatty acids (FFA) (NCT01419535)
Timeframe: 9 days
| Intervention | mmol/l·μU/l (Mean) |
|---|---|
| Post-mifepristone | 49.9 |
| Post-placebo | 65.5 |
The Adipo-SI was calculated as ratio of the slope of the linear decrease in natural log transformed FFA [Ln (FFA) slope] during the first 90 minutes of the FSIVGTT and the area under the curve (AUC) of insulin during that 90-minute period (AUC Insulin 0-90 min). (NCT01419535)
Timeframe: 9 days
| Intervention | ln(mmol /uU/mL*min)*10^8 (Mean) |
|---|---|
| Post-mifepristone | 61.7 |
| Post-placebo | 42.8 |
Fasting insulin after study agent administration compared to baseline (NCT01419535)
Timeframe: 9 days
| Intervention | pmol/L (Mean) |
|---|---|
| Post-mifepristone | 95.6 |
| Post-placebo | 142.8 |
fasting plasma glucose after study agent compared to baseline (NCT01419535)
Timeframe: Nine days
| Intervention | mg/dL (Mean) |
|---|---|
| Post-mifepristone | 100.4 |
| Post-placebo | 107.8 |
insulin sensitivity index based on the effect of insulin on glucose during frequently sampled intravenous glucose tolerance test (FSIVGTT) (NCT01419535)
Timeframe: Nine days
| Intervention | min-1·μU·ml-1 (Mean) |
|---|---|
| Post-mifepristone | 1.49 |
| Post-placebo | 1.41 |
HOMA-IR is an index of insulin resistance, measured as glucose in mmol/L x insulin in mIU/mL)/22.5. HOMA-IR > 2.5 indicates insulin resistance. (NCT01419535)
Timeframe: 9 days
| Intervention | units on a scale (Mean) |
|---|---|
| Post-mifepristone | 3.58 |
| Post-placebo | 5.78 |
Change in hyperglycemia assessed by HbA1c, also known as glycated hemoglobin (NCT01990560)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | percentage of red blood cells (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | 6 months | |
| Mifepristone | 6.2 | 6.1375 | 6.125 |
Change in metabolic syndrome as assessed by BMI (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | kg/m2 (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 35.1538 | 34.5463 |
Change in Quality of Life - as assessed by the Cushing's Quality of Life questionnaire (CushingQoL). Patient completed questionnaire, 12 items, each scored on a 5 point score, resulting in a score of 12 (worst) to 60 (best) where higher scores indicate more favorable QOL. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 37.2857 | 38.7857 |
Change in metabolic syndrome as assessed by fasting lipid profile which includes Low-density lipoproteins ( LDL), High-density lipoproteins (HDL), and Triglycerides (Trigs) levels, and total cholesterol which is the sum of HDL plus LDL and 20% of trigs. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total Cholesterol Baseline | Total Cholesterol 6 months | LDL baseline | LDL 6 months | HDL Baseline | HDL 6 months | Trigs Baseline | Trigs 6 months | |
| Mifepristone | 178.63 | 171.43 | 97.88 | 104.37 | 59.13 | 46.86 | 107.88 | 100.29 |
Change in hyperglycemia assessed by Homeostatic Model Assessment of Insulin Resistance, HOMA-IR (a validated assessment of insulin resistance). HOMA-IR = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | HOMA-IR score (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 2.418 | 1.465 |
Change in Quality of Life as assessed by the Hospital Anxiety and Depression Scale (HADS). Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 16.2857 | 11.1667 |
Change in Quality of Life as assessed by the Nottingham Health Profile (NHP) which is a patient reported questionnaire to measure a patient's view of their own health status. There are 6 sections (Energy level, Pain, Emotional Reaction, Sleep, Social Isolation, and Physical Abilities. All questions have only yes/no answer options and each section score is weighted so that the possible score range for any section is 0-100. The higher the score, the greater the number and severity of problems. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Energy Level (EL) Baseline | EL 6 months | Pain (P) Baseline | P 6 months | Emotional Reaction (ER) Baseline | ER 6 months | Sleep (S) Baseline | S 6 months | Social Isolation (SI) Baseline | SI 6 months | Physical Abilities (PA) Baseline | PA 6 months | |
| Mifepristone | 32.60 | 45.40 | 24.88 | 32.08 | 27.03 | 35.09 | 24.87 | 31.15 | 20.09 | 31.15 | 23.06 | 27.49 |
Change in Quality of Life as assessed by the Beck Depression Inventory. a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 16.1429 | 11.7143 |
Change in Quality of Life - as assessed by the State Trait Anxiety Inventory (STAI). The State-Trait Anxiety Inventory both state and trait anxiety separately. Each type of anxiety has its own scale of 20 different questions that are scored and averaged. Total scores range from 20 to 80, with higher scores correlating with greater anxiety. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 25.4286 | 28.8571 |
Change in metabolic syndrome as assessed by waist circumference (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 103.25 | 99.3125 |
Change in metabolic syndrome as assessed by weight (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | kg (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 99.57 | 97.75 |
1 review available for uric acid and Cushing Syndrome
| Article | Year |
|---|---|
Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipokines; Birth Weight; Blood Coagulation Disorders; | 2009 |
1 trial available for uric acid and Cushing Syndrome
| Article | Year |
|---|---|
Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome.
Topics: Absorptiometry, Photon; Adipose Tissue; Adrenal Gland Neoplasms; Adult; Aging; Blood Pressure; Body | 2001 |
7 other studies available for uric acid and Cushing Syndrome
| Article | Year |
|---|---|
Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure.
Topics: Adult; Analysis of Variance; Body Mass Index; Calcium; Citric Acid; Cushing Syndrome; Cystine; Cysti | 2003 |
O-P'DDD THERAPY IN CUSHING'S SYNDROME AND IN OBESITY WITH CUSHINGOID CHANGES.
Topics: Adrenocorticotropic Hormone; Blood Chemical Analysis; Carbohydrate Metabolism; Child; Cushing Syndro | 1964 |
[Thyroid and adrenal diagnosis in obesity are not worth while].
Topics: Adult; Aged; Body Weight; Cushing Syndrome; Diabetes Complications; Female; Humans; Hyperlipidemias; | 1983 |
Erythrodermic psoriasis associated with hyperuricemia and Iatrogenic Cushing's syndrome due to topical corticosteroid therapy.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Cushing Syndrome; Dermatitis, | 1996 |
Increased urate excretion after o,p'-DDD.
Topics: Adult; Cushing Syndrome; Female; Humans; Mitotane; Uric Acid | 1978 |
Efficacy of amino-glutethimide in the ectopic ACTH syndrome.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenocorticotropic Hormone; Adult; Aminoglutethimide; A | 1968 |
[Clarification of a hypertension].
Topics: Aldosterone; Angiotensin II; Aortic Coarctation; Blood Pressure Determination; Creatinine; Cushing S | 1970 |